pimurutamab
- Generic Name
- pimurutamab
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Phase 1
Completed
- Conditions
- Solid Tumour
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT02648490
- Locations
- 🇺🇸
Henlix, Inc., Fremont, California, United States
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath